Incidence of Liver and Non-liver Cancers After Hepatitis C Virus Eradication: A Population-Based Cohort Study.
Jose RíosVíctor SapenaZoe MariñoJordi BruixXavier FornsRosa Morros-PedrosMaria ReigFerràn TorresCaridad PontesPublished in: Drugs - real world outcomes (2024)
Results showed that overall cancer and hepatocellular carcinoma incidence in Catalonia was significantly higher among HCV-treated patients compared with matched non-HCV-infected controls, and risks were higher in patients with cirrhosis. An increased awareness of the potential occurrence of uncommon malignant events and monitoring after HCV eradication therapy may benefit patients.
Keyphrases
- hepatitis c virus
- end stage renal disease
- newly diagnosed
- ejection fraction
- human immunodeficiency virus
- prognostic factors
- peritoneal dialysis
- risk assessment
- squamous cell carcinoma
- stem cells
- helicobacter pylori infection
- papillary thyroid
- bone marrow
- human health
- young adults
- climate change
- hiv infected
- cell therapy
- childhood cancer
- lymph node metastasis